CD40L adjuvant for DNA/MVA vaccine: enhanced protection from acquisition of neutralization sensitive & neutralization resistant mucosal SIV infections

• Type of Material: Poster
• Authors: S Kwa, Emory University; S Sadagopal, Emory University; J Hong, Emory University; Sailaja Gangadhara, Emory University; R Basu, Emory University; Lilin Lai, Emory University; S Iyer, Emory University; Koichi Araki, Emory University; PL Earl, NIH; L Wyatt, NIH; Francois Villinger, Emory University; B Moss, NIH; Rafi Ahmed, Emory University; Rama Amara, Emory University
• Language: English
• Date: 2012-09-13
• Publisher: Emory University Libraries
• Copyright Statement: ©2012 Kwa et al; licensee BioMed Central Ltd.
• License: Creative Commons Attribution 2.0 Generic
• Final Published Version (URL): https://retrovirology.biomedcentral.com/articles/10.1186/1742-4690-9-S2-P365
• Conference or Event Name: AIDS Vaccine 2012, Boston, MA, USA. 9-12
• Keywords: Life Sciences & Biomedicine; Virology; Science & Technology
• Research Categories: Health Sciences, Immunology; Health Sciences, General

Abstract

Generating highly functional antibodies against HIV-1 is critical to prevent infection. Here we evaluated the ability of CD40L (a co-stimulatory molecule for B cells and dendritic cells) as an adjuvant to prevent mucosal infection from neutralization-susceptible (SIVE660) and neutralization-resistant (SIV251) SIVs.